The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Complicated Skin And Skin Structure Infections Drugs Market Grow Between 2026 And 2030?
The complicated skin and skin structure infections drugs market has shown strong growth recently. It is expected to grow from $10.36 billion in 2025 to $11.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth can be linked to factors such as a high frequency of bacterial skin infections, rising awareness regarding healthcare-associated infections, an increase in hospital admissions due to csssi, the adoption of intravenous antibiotic therapy, and the availability of generic antibiotics.
The complicated skin and skin structure infections drugs market size is anticipated to undergo significant expansion in the foreseeable future, with projections showing it will reach $16.61 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.1%. This growth during the forecast period can be attributed to the emergence of multidrug-resistant bacteria, advancements in targeted antibiotic therapies, the integration of digital health for infection management, a rising demand for outpatient treatment options, and the expansion of biologics and novel antimicrobial agents. Major trends expected in this period include the increasing prevalence of antibiotic-resistant skin infections, the development of new antibiotics for deep tissue infections, the adoption of advanced drug delivery systems, a rise in both hospitalization and outpatient care for csssi, and a focus on patient-centric therapeutic regimens.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12940&type=smp
Which Drivers Are Supporting The Complicated Skin And Skin Structure Infections Drugs Market Growth?
The rising occurrence of skin conditions is anticipated to fuel the expansion of the complicated skin and skin structure infections drugs market in the future. Skin diseases are health issues that impact the skin’s appearance, composition, and operation, potentially affecting the skin itself, as well as hair, nails, and associated tissues. Various antibiotic medications are employed to combat resistant bacteria found in cSSSI. Consequently, an increase in skin disease incidences could result in approvals for new cSSSI drugs, heightened public awareness, and encouragement for prompt identification of complicated skin and skin structure infections. For example, data from February 2023, provided by Cancer Research UK, a UK-based cancer research organization, projects an annual rise in new melanoma skin cancer cases within the UK from approximately 20,800 cases between 2023-2025 to around 26,500 cases by 2038-2040. This translates to an estimated 9% increase in melanoma incidence rates, reaching 33 cases per 100,000 people each year by 2038-2040. Hence, the expanding occurrence of skin diseases is a key factor propelling the growth of the complicated skin and skin structure infections drugs market.
How Is The Complicated Skin And Skin Structure Infections Drugs Market Organized By Segment Classification?
The complicated skin and skin structure infections drugs market covered in this report is segmented –
1) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Linezolid, Other Active Ingredients
2) By Route of Administration: Oral, Topical, Parenteral
3) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Delafloxacin: Delafloxacin Oral Tablets, Delafloxacin Injectable Form
2) By Vancomycin: Vancomycin Oral Solution, Vancomycin Injection
3) By Ceftaroline Fosamil: Ceftaroline Fosamil Injection
4) By Linezolid: Linezolid Oral Tablets, Linezolid Injectable Form
5) By Other Active Ingredients: Daptomycin, Tigecycline, Teicoplanin
What Trends Are Transforming The Complicated Skin And Skin Structure Infections Drugs Market?
Leading companies operating in the complicated skin and skin structure infections drugs market are creating novel products, such as dalbavancin, to gain a competitive advantage. Dalbavancin is a second-generation semi-synthetic lipoglycopeptide antibiotic that functions by disrupting bacterial cell wall synthesis, effectively eradicating gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), making it beneficial in addressing acute bacterial skin and skin structure infections (ABSSSI). For instance, in January 2023, AbbVie Inc., a US-based pharmaceutical company, announced the expansion of Xydalba (dalbavancin for injection) approval for pediatric patients throughout Europe. Xydalba is an intravenous therapy designated for acute bacterial skin and skin structure infections in adults and children from three months of age. Its characteristics include a long half-life permitting infrequent dosing, strong activity against resistant gram-positive pathogens, and a favorable safety profile, assisting clinicians in efficiently managing complicated infections.
Who Are The Industry Participants Involved In The Complicated Skin And Skin Structure Infections Drugs Market?
Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy’s Laboratories Ltd, Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH
Get The Full Complicated Skin And Skin Structure Infections Drugs Market Report:
Which Region Holds The Highest Market Share In The Complicated Skin And Skin Structure Infections Drugs Market?
Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 202. The regions covered in the complicated skin and skin structure infections drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Complicated Skin And Skin Structure Infections Drugs Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Complicated Skin And Skin Structure Infections Drugs Market 2026, By The Business Research Company
Complicated Skin And Skin Structure Infections Drugs Market Report 2026
Acute Bacterial Skin And Skin Structure Infections Market Report 2026
Dermatology Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model